Sign up to save your podcasts
Or
Share How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Subscribe to Biotech Blueprint for free at biotechblueprint.com.
About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how multi-antigen mRNA vaccines aim to control reactivation. We also cover Moderna’s CMV Phase 3 (mRNA-1647) as a platform stress test and the rise of personalized neoantigen cancer vaccines (V940) that cut melanoma recurrence vs Keytruda alone in Phase 2b and are now in Phase 3. What success here would mean for public health, operations, and the mRNA platform.
View all episodes
By Katerina RoznikSubscribe to Biotech Blueprint for free at biotechblueprint.com.
About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how multi-antigen mRNA vaccines aim to control reactivation. We also cover Moderna’s CMV Phase 3 (mRNA-1647) as a platform stress test and the rise of personalized neoantigen cancer vaccines (V940) that cut melanoma recurrence vs Keytruda alone in Phase 2b and are now in Phase 3. What success here would mean for public health, operations, and the mRNA platform.